

# Charles J Sherr

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5036870/publications.pdf>

Version: 2024-02-01

173  
papers

44,354  
citations

10389

72  
h-index

5829

161  
g-index

175  
all docs

175  
docs citations

175  
times ranked

29559  
citing authors

#	ARTICLE	IF	CITATIONS
1	Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. <i>Cell</i> , 2020, 181, 424-441.e21.	28.9	216
2	Surprising regulation of cell cycle entry. <i>Science</i> , 2019, 366, 1315-1316.	12.6	8
3	Sexually dimorphic tumor suppression by small mitochondrial Arf. <i>Oncotarget</i> , 2019, 10, 1235-1237.	1.8	0
4	The D-Type Cyclins: A Historical Perspective. <i>Current Cancer Research</i> , 2018, , 1-26.	0.2	5
5	NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. <i>Science</i> , 2018, 362, 1416-1422.	12.6	267
6	Acquired palbociclib resistance in KRAS-mutant lung cancer. <i>Oncotarget</i> , 2018, 9, 32734-32735.	1.8	3
7	Mouse medulloblastoma driven by CRISPR activation of cellular Myc. <i>Scientific Reports</i> , 2018, 8, 8733.	3.3	17
8	Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma. <i>Cell Reports</i> , 2017, 18, 2907-2917.	6.4	61
9	Small mitochondrial Arf (smArf) protein corrects p53-independent developmental defects of <i>Arf</i> tumor suppressor-deficient mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 7420-7425.	7.1	9
10	Cell Cycle-Targeted Cancer Therapies. <i>Annual Review of Cancer Biology</i> , 2017, 1, 41-57.	4.5	88
11	A New Cell-Cycle Target in Cancer – Inhibiting Cyclin-Dependent Kinases 4 and 6. <i>New England Journal of Medicine</i> , 2016, 375, 1920-1923.	27.0	36
12	Targeting CDK4 and CDK6: From Discovery to Therapy. <i>Cancer Discovery</i> , 2016, 6, 353-367.	9.4	717
13	Abstract IA21: Mitogenic signaling and the RB/p53 network. , 2016, , .		0
14	Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL. <i>Blood</i> , 2015, 125, 1444-1451.	1.4	35
15	Forging a signature of in vivo senescence. <i>Nature Reviews Cancer</i> , 2015, 15, 397-408.	28.4	775
16	Simultaneous Gene Editing by Injection of mRNAs Encoding Transcription Activator-Like Effector Nucleases into Mouse Zygotes. <i>Molecular and Cellular Biology</i> , 2014, 34, 1649-1658.	2.3	26
17	Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 263-271.	1.5	9
18	CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. <i>Genes and Development</i> , 2014, 28, 1800-1814.	5.9	167

#	ARTICLE	IF	CITATIONS
19	Epigenetic regulation of the Ink4a-Arf (Cdkn2a) tumor suppressor locus in the initiation and progression of Notch1-driven T cell acute lymphoblastic leukemia. <i>Experimental Hematology</i> , 2013, 41, 377-386.	0.4	12
20	<i>Arf</i> tumor suppressor and miR-205 regulate cell adhesion and formation of extraembryonic endoderm from pluripotent stem cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E1112-21.	7.1	27
21	Prevention Of Minimal Residual Disease In Ph+ ALL. <i>Blood</i> , 2013, 122, 1265-1265.	1.4	0
22	<i>Ink4a-Arf</i> locus in cancer and aging. <i>Wiley Interdisciplinary Reviews: Developmental Biology</i> , 2012, 1, 731-741.	5.9	85
23	How politics trumped peer review at Texas cancer institute. <i>BMJ, The</i> , 2012, 345, e7334-e7334.	6.0	0
24	Host Thiopurine Methyltransferase Status Affects Mercaptopurine Antileukemic Effectiveness. <i>Blood</i> , 2012, 120, 3560-3560.	1.4	0
25	Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Blood</i> , 2011, 117, 3585-3595.	1.4	73
26	Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies. <i>Blood</i> , 2011, 117, 5453-5462.	1.4	30
27	Expression of Arf Tumor Suppressor in Spermatogonia Facilitates Meiotic Progression in Male Germ Cells. <i>PLoS Genetics</i> , 2011, 7, e1002157.	3.5	27
28	Developmental strategies for evasion of Arf tumor suppression. <i>Cell Cycle</i> , 2010, 9, 14-15.	2.6	8
29	Atoh1 Inhibits Neuronal Differentiation and Collaborates with Gli1 to Generate Medulloblastoma-Initiating Cells. <i>Cancer Research</i> , 2010, 70, 5618-5627.	0.9	87
30	Transient expression of the <i>Arf</i> tumor suppressor during male germ cell and eye development in <i>Arf-Cre</i> reporter mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 6285-6290.	7.1	40
31	Two Tumor Suppressors, p27Kip1 and Patched-1, Collaborate to Prevent Medulloblastoma. <i>Molecular Cancer Research</i> , 2009, 7, 33-40.	3.4	55
32	Rescue of key features of the p63-null epithelial phenotype by inactivation of Ink4a and Arf. <i>EMBO Journal</i> , 2009, 28, 1904-1915.	7.8	66
33	Stage-specific Arf tumor suppression in Notch1-induced T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2009, 114, 4451-4459.	1.4	23
34	Developmentally Restricted Protection From Notch1-Induced T Cell Acute Lymphoblastic Leukemia by the Arf Tumor Suppressor. <i>Blood</i> , 2009, 114, 143-143.	1.4	13
35	Abstract A253: Acquired Bcr-Abl kinase domain mutations are not responsible for persistence of dasatinib-refractory disease in murine Ph+ALL. , 2009, , .		0
36	Hzf regulates adipogenesis through translational control of C/EBPβ. <i>EMBO Journal</i> , 2008, 27, 1481-90.	7.8	22

#	ARTICLE	IF	CITATIONS
37	BCR-ABL and CDKN2A: a dropped connection. <i>Nature Reviews Cancer</i> , 2008, 8, 563-563.	28.4	9
38	Differential post-transcriptional regulation of two Ink4 proteins, p18Ink4c and p19Ink4d. <i>Cell Cycle</i> , 2008, 7, 3737-3746.	2.6	16
39	Failure of CDKN2A/B (INK4A/B)-ARF-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. <i>Genes and Development</i> , 2008, 22, 1411-1415.	5.9	84
40	Arf-induced turnover of the nucleolar nucleophosmin-associated SUMO-2/3 protease Senp3. <i>Cell Cycle</i> , 2008, 7, 3378-3387.	2.6	64
41	Genetic Alterations in Mouse Medulloblastomas and Generation of Tumors De novo from Primary Cerebellar Granule Neuron Precursors. <i>Cancer Research</i> , 2007, 67, 2676-2684.	0.9	66
42	Cytokine-dependent imatinib resistance in mouse BCR-ABL <sup>+</sup> , Arf <sup>-/-</sup> lymphoblastic leukemia. <i>Genes and Development</i> , 2007, 21, 2283-2287.	5.9	166
43	Regulation of the Arf tumor suppressor in $\frac{1}{4}$ -Myc transgenic mice: longitudinal study of Myc-induced lymphomagenesis. <i>Blood</i> , 2007, 109, 792-794.	1.4	17
44	The Arf Tumor Suppressor in Acute Leukemias: Insights from Mouse Models of Bcr-ABL-Induced Acute Lymphoblastic Leukemia. <i>Advances in Experimental Medicine and Biology</i> , 2007, 604, 107-114.	1.6	13
45	Autophagy by ARF: A Short Story. <i>Molecular Cell</i> , 2006, 22, 436-437.	9.7	20
46	Divorcing ARF and p53: an unsettled case. <i>Nature Reviews Cancer</i> , 2006, 6, 663-673.	28.4	535
47	The CDK Inhibitor p18Ink4c is a Tumor Suppressor in Medulloblastoma. <i>Cell Cycle</i> , 2006, 5, 363-365.	2.6	32
48	Hzf, a p53-Responsive Gene, Regulates Maintenance of the G2 Phase Checkpoint Induced by DNA Damage. <i>Molecular and Cellular Biology</i> , 2006, 26, 502-512.	2.3	30
49	Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 6688-6693.	7.1	182
50	N-Myc and the cyclin-dependent kinase inhibitors p18Ink4c and p27Kip1 coordinately regulate cerebellar development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 11579-11583.	7.1	69
51	Inactivation of the Arf Tumor Suppressor in Mouse BCR-ABL(+) B Cells Greatly Increases the Frequency of Leukemia-Initiating Cells and Confers Imatinib Resistance In Vivo.. <i>Blood</i> , 2006, 108, 385-385.	1.4	1
52	The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. <i>Genes and Development</i> , 2005, 19, 2656-2667.	5.9	133
53	Tbx3, the ulnar-mammary syndrome gene, and Tbx2 interact in mammary gland development through a p19Arf/p53-independent pathway. <i>Developmental Dynamics</i> , 2005, 234, 922-933.	1.8	72
54	Ras-Raf-Arf Signaling Critically Depends on the Dmp1 Transcription Factor. <i>Molecular and Cellular Biology</i> , 2005, 25, 220-232.	2.3	109

#	ARTICLE	IF	CITATIONS
55	Myeloid Leukemia-Associated Nucleophosmin Mutants Perturb p53-Dependent and Independent Activities of the Arf Tumor Suppressor Protein. <i>Cell Cycle</i> , 2005, 4, 1593-1598.	2.6	95
56	Sumoylation induced by the Arf tumor suppressor: A p53-independent function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 7689-7694.	7.1	107
57	Living with or without cyclins and cyclin-dependent kinases. <i>Genes and Development</i> , 2004, 18, 2699-2711.	5.9	945
58	Erk2 Signaling and Early Embryo Stem Cell Self-Renewal. <i>Cell Cycle</i> , 2004, 3, 239-241.	2.6	29
59	N-Terminal Polyubiquitination of the ARF Tumor Suppressor, A Natural Lysine-Less Protein. <i>Cell Cycle</i> , 2004, 3, 1367-1369.	2.6	18
60	AnArfGFP/GFPIndicator Mouse Reveals that theArfTumor Suppressor Monitors Latent Oncogenic Signals In Vivo. <i>Cell Cycle</i> , 2004, 3, 237-238.	2.6	4
61	Physical and Functional Interactions of the Arf Tumor Suppressor Protein with Nucleophosmin/B23. <i>Molecular and Cellular Biology</i> , 2004, 24, 985-996.	2.3	351
62	Antagonism of Myc functions by Arf. <i>Cancer Cell</i> , 2004, 6, 309-311.	16.8	36
63	Monoclonal Antibodies to the Mouse p19ArfTumor Suppressor Protein. <i>Hybridoma</i> , 2004, 23, 293-300.	0.4	26
64	N-terminal polyubiquitination and degradation of the Arf tumor suppressor. <i>Genes and Development</i> , 2004, 18, 1862-1874.	5.9	180
65	Principles of Tumor Suppression. <i>Cell</i> , 2004, 116, 235-246.	28.9	850
66	Expression arrays illuminate a way forward for mantle cell lymphoma. <i>Cancer Cell</i> , 2003, 3, 100-102.	16.8	4
67	Bared essentials of CDK2 and cyclin E. <i>Nature Genetics</i> , 2003, 35, 8-9.	21.4	27
68	Tumor suppression by Ink4aâ€“Arf: progress and puzzles. <i>Current Opinion in Genetics and Development</i> , 2003, 13, 77-83.	3.3	666
69	Nucleolar Arf Tumor Suppressor Inhibits Ribosomal RNA Processing. <i>Molecular Cell</i> , 2003, 11, 415-424.	9.7	267
70	Myc-Mediated Proliferation and Lymphomagenesis, but Not Apoptosis, Are Compromised by E2f1 Loss. <i>Molecular Cell</i> , 2003, 11, 905-914.	9.7	91
71	Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 15930-15935.	7.1	139
72	Oncogenic Potential of the c-FMS Proto-Oncogene (CSF-1 Receptor). <i>Cell Cycle</i> , 2003, 2, 5-6.	2.6	14

#	ARTICLE	IF	CITATIONS
73	Arf induces p53-dependent and -independent antiproliferative genes. <i>Cancer Research</i> , 2003, 63, 1046-53.	0.9	92
74	Hemangiosarcomas, medulloblastomas, and other tumors in Ink4c/p53-null mice. <i>Cancer Research</i> , 2003, 63, 5420-7.	0.9	55
75	D1 in G2. <i>Cell Cycle</i> , 2002, 1, 32-34.	2.6	23
76	The RB and p53 pathways in cancer. <i>Cancer Cell</i> , 2002, 2, 103-112.	16.8	1,473
77	The RING domain of Mdm2 can inhibit cell proliferation. <i>Cancer Research</i> , 2002, 62, 1222-30.	0.9	59
78	Parsing Ink4a/Arf. <i>Cell</i> , 2001, 106, 531-534.	28.9	69
79	The INK4a/ARF network in tumour suppression. <i>Nature Reviews Molecular Cell Biology</i> , 2001, 2, 731-737.	37.0	890
80	Control of Spermatogenesis in Mice by the Cyclin D-Dependent Kinase Inhibitors p18 Ink4c and p19 Ink4d. <i>Molecular and Cellular Biology</i> , 2001, 21, 3244-3255.	2.3	103
81	Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. <i>Genes and Development</i> , 2001, 15, 2934-2939.	5.9	101
82	p53-independent functions of the p19ARF tumor suppressor. <i>Genes and Development</i> , 2000, 14, 2358-2365.	5.9	317
83	<i>Ink4d</i> -Deficient Mice Are Fertile Despite Testicular Atrophy. <i>Molecular and Cellular Biology</i> , 2000, 20, 372-378.	2.3	129
84	Cooperative Signals Governing ARF-Mdm2 Interaction and Nucleolar Localization of the Complex. <i>Molecular and Cellular Biology</i> , 2000, 20, 2517-2528.	2.3	260
85	The ARF/p53 pathway. <i>Current Opinion in Genetics and Development</i> , 2000, 10, 94-99.	3.3	612
86	Cellular Senescence. <i>Cell</i> , 2000, 102, 407-410.	28.9	720
87	Oncogenic Ras Induces p19ARF and Growth Arrest in Mouse Embryo Fibroblasts Lacking p21Cip1 and p27Kip1 without Activating Cyclin D-dependent Kinases. <i>Journal of Biological Chemistry</i> , 2000, 275, 27473-27480.	3.4	60
88	Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. <i>Genes and Development</i> , 2000, 14, 1797-1809.	5.9	89
89	Nucleolar Arf sequesters Mdm2 and activates p53. <i>Nature Cell Biology</i> , 1999, 1, 20-26.	10.3	854
90	A rate limiting function of cdc25A for S phase entry inversely correlates with tyrosine dephosphorylation of Cdk2. <i>Oncogene</i> , 1999, 18, 573-582.	5.9	94

#	ARTICLE	IF	CITATIONS
91	p27KIP1 Deletions in Childhood Acute Lymphoblastic Leukemia. <i>Neoplasia</i> , 1999, 1, 253-261.	5.3	37
92	Cloning and chromosomal localization of the gene encoding human cyclin D-binding Myb-like protein (hDMP1). <i>Gene</i> , 1999, 229, 223-228.	2.2	36
93	Cyclin D- and E-Dependent Kinases and the p57 <sup>KIP2</sup> Inhibitor: Cooperative Interactions In Vivo. <i>Molecular and Cellular Biology</i> , 1999, 19, 353-363.	2.3	63
94	CDK inhibitors: positive and negative regulators of G1-phase progression. <i>Genes and Development</i> , 1999, 13, 1501-1512.	5.9	5,227
95	Tumor surveillance via the ARF $\rightarrow$ p53 pathway. <i>Genes and Development</i> , 1998, 12, 2984-2991.	5.9	641
96	Regulation of the CD13/Aminopeptidase N Gene by DMP1, a Transcription Factor Antagonized by D-Type Cyclins. <i>Journal of Biological Chemistry</i> , 1998, 273, 29188-29194.	3.4	40
97	Gene Expression and Cell Cycle Arrest Mediated by Transcription Factor DMP1 Is Antagonized by D-Type Cyclins through a Cyclin-Dependent-Kinase-Independent Mechanism. <i>Molecular and Cellular Biology</i> , 1998, 18, 1590-1600.	2.3	158
98	Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19. <i>Cell</i> , 1997, 91, 649-659.	28.9	1,519
99	Features of Macrophage Differentiation Induced by p19INK4d, a Specific Inhibitor of Cyclin D $\rightarrow$ Dependent Kinases. <i>Blood</i> , 1997, 90, 126-137.	1.4	48
100	Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. <i>Oncogene</i> , 1997, 15, 203-211.	5.9	527
101	Features of Macrophage Differentiation Induced by p19INK4d, a Specific Inhibitor of Cyclin D $\rightarrow$ Dependent Kinases. <i>Blood</i> , 1997, 90, 126-137.	1.4	19
102	Cancer Cell Cycles. <i>Science</i> , 1996, 274, 1672-1677.	12.6	4,932
103	D-type cyclins. <i>Trends in Biochemical Sciences</i> , 1995, 20, 187-190.	7.5	905
104	Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. <i>Cell</i> , 1995, 83, 993-1000.	28.9	1,393
105	Molecular Cloning, Expression Pattern, and Chromosomal Localization of Human CDKN2D/INK4d, an Inhibitor of Cyclin D-Dependent Kinases. <i>Genomics</i> , 1995, 29, 623-630.	2.9	58
106	The ins and outs of RB: coupling gene expression to the cell cycle clock. <i>Trends in Cell Biology</i> , 1994, 4, 15-18.	7.9	135
107	Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. <i>Cell</i> , 1994, 79, 487-496.	28.9	741
108	G1 phase progression: Cycling on cue. <i>Cell</i> , 1994, 79, 551-555.	28.9	2,668

#	ARTICLE	IF	CITATIONS
109	Editorial overview checks and balances. <i>Current Opinion in Cell Biology</i> , 1994, 6, 833-835.	5.4	10
110	Monoclonal Antibodies to Mammalian D-Type G1 Cyclins. <i>Hybridoma</i> , 1994, 13, 37-44.	0.6	28
111	Control of G1 Progression by Mammalian D-Type Cyclins. , 1994, , 17-23.		3
112	Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. <i>Cell</i> , 1993, 73, 487-497.	28.9	1,056
113	Mammalian G1 cyclins. <i>Cell</i> , 1993, 73, 1059-1065.	28.9	1,994
114	Identification and properties of an atypical catalytic subunit (p34 <sup>PSK-J3</sup> /cdk4) for mammalian D type G1 cyclins. <i>Cell</i> , 1992, 71, 323-334.	28.9	888
115	Genomic organization, chromosomal localization, and independent expression of human cyclin D genes. <i>Genomics</i> , 1992, 13, 565-574.	2.9	246
116	Regulation of <i>CYCL</i> /Cyclin D Genes by Colony-Stimulating Factor 1. Novartis Foundation Symposium, 1992, 170, 209-219.	1.1	11
117	Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. <i>Cell</i> , 1991, 65, 701-713.	28.9	1,179
118	Myc rescue of a mutant CSF-1 receptor impaired in mitogenic signalling. <i>Nature</i> , 1991, 353, 361-363.	27.8	171
119	Regulation of mononuclear phagocyte proliferation by colony-stimulating factor-1. <i>International Journal of Cell Cloning</i> , 1990, 8, 46-62.	1.6	22
120	Functional Expression of the Human Receptor for Colony-Stimulating Factor 1 (CSF-1) in Hamster Fibroblasts: CSF-1 Stimulates Na <sup>+</sup> /H <sup>+</sup> exchange and DNA-Synthesis in the Absence of Phosphoinositide Breakdown. <i>Growth Factors</i> , 1990, 2, 289-300.	1.7	2
121	Signal-Response Coupling Mediated by the Transduced Colony-Stimulating Factor-1 Receptor and its Oncogenic Variants in Naive Cells. Novartis Foundation Symposium, 1990, 148, 96-109.	1.1	0
122	The Mononuclear Phagocyte Colony-Stimulating Factor (CSF-1, M-CSF). <i>Hematology/Oncology Clinics of North America</i> , 1989, 3, 479-493.	2.2	31
123	The Macrophage Colony Stimulating Factor, CSF-1, and Its Receptor (c-fms). , 1989, , 193-207.		0
124	Colony-stimulating factor-1 receptor (c-fms). <i>Journal of Cellular Biochemistry</i> , 1988, 38, 179-187.	2.6	51
125	The fms oncogene. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 1988, 948, 225-243.	7.4	27
126	Tandem linkage of human CSF-1 receptor (c-fms) and PDGF receptor genes. <i>Cell</i> , 1988, 55, 655-661.	28.9	175

#	ARTICLE	IF	CITATIONS
127	A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene) Tj ETQq1 1 0.784314 rgBT/Overlook	28.9	257
128	The colony-stimulating factor 1 (CSF-1) receptor (c-fms protooncogene product) and its ligand. Journal of Cell Science, 1988, 1988, 27-44.	2.0	30
129	Leukemia and lymphoma 1987. Cell, 1987, 48, 727-729.	28.9	4
130	Multilineage hematopoietic disorders induced by transplantation of bone marrow cells expressing the v-fms oncogene. Cell, 1987, 51, 663-673.	28.9	74
131	Transformation by the v-fms oncogene product: An analog of the CSF-1 receptor. Journal of Cellular Biochemistry, 1987, 33, 109-115.	2.6	6
132	Fibroblast and hematopoietic cell transformation by the fms oncogene (CSF-1 receptor). Journal of Cellular Physiology, 1987, 133, 83-87.	4.1	4
133	Transforming potential of the c-fms proto-oncogene (CSF-1 receptor). Nature, 1987, 325, 549-552.	27.8	370
134	Relationship of the c-fms Protooncogene Product to the CSF-1 Receptor. , 1987, , 81-91.		0
135	Antibodies to distal carboxyl terminal epitopes in the v-fms-coded glycoprotein do not cross-react with the c-fms gene product. Virology, 1986, 152, 432-445.	2.4	45
136	The v-fms oncogene induces factor independence and tumorigenicity in CSF-1 dependent macrophage cell line. Nature, 1986, 324, 377-380.	27.8	117
137	The c-fms Proto-Oncogene and the CSF-1 Receptor. , 1986, , 93-99.		4
138	Transmembrane orientation of glycoproteins encoded by the v-fms oncogene. Cell, 1985, 40, 971-981.	28.9	95
139	Expression of the human c-fms proto-oncogene in hematopoietic cells and its deletion in the 5qâ syndrome. Cell, 1985, 42, 421-428.	28.9	181
140	The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF 1. Cell, 1985, 41, 665-676.	28.9	1,602
141	For the public record: Status of oncogene research. BioEssays, 1984, 1, 133-135.	2.5	0
142	Transformation by feline retroviruses. , 1984, 26, 45-58.		0
143	Mutant Feline Sarcoma Provirus Containing the Viral Oncogene (v-fes) and Either Feline or Murine Control Elements. Journal of Virology, 1983, 45, 1004-1016.	3.4	37
144	Nucleotide sequences of feline retroviral oncogenes (v-fes) provide evidence for a family of tyrosine-specific protein kinase genes. Cell, 1982, 30, 775-785.	28.9	217

#	ARTICLE	IF	CITATIONS
145	Preparation of rat monoclonal antibodies to epitopes encoded by the viral oncogene (v-fms) of McDonough feline sarcoma virus. <i>Journal of Cellular Biochemistry</i> , 1982, 19, 275-280.	2.6	4
146	[35] Purification and assay of murine leukemia viruses. <i>Methods in Enzymology</i> , 1979, 58, 412-424.	1.0	11
147	Activation of endogenous type-C viral p30 antigen in chemically-induced rat hepatocellular carcinomas. <i>International Journal of Cancer</i> , 1978, 21, 756-761.	5.1	1
148	MAC-1, a new genetically transmitted type C virus of primates: "low frequency" activation from stump-tail monkey cell cultures. <i>Cell</i> , 1978, 13, 775-782.	28.9	77
149	A gene (Bevi) on human chromosome 6 is an integration site for baboon type C DNA provirus in human cells. <i>Cell</i> , 1978, 14, 995-1005.	28.9	57
150	Endogenous feline (RD-114) and baboon type C viruses have related specific RNA-binding proteins and genome binding sites. <i>Virology</i> , 1978, 84, 99-107.	2.4	9
151	Isolation and characterization of a new type D retrovirus from the Asian primate, <i>Presbytis obscurus</i> (spectacled langur). <i>Virology</i> , 1978, 84, 189-194.	2.4	88
152	Phosphorylation of murine type C viral p12 proteins regulates their extent of binding to the homologous viral RNA. <i>Cell</i> , 1977, 10, 487-496.	28.9	113
153	A new genetic locus, bevi, on human chromosome 6 which controls the replication of baboon type C virus in human cells. <i>Cell</i> , 1977, 12, 251-262.	28.9	40
154	A new class of murine retroviruses: Immunological and biochemical comparison of novel isolates from <i>Mus cervicolor</i> and <i>Mus caroli</i> . <i>Virology</i> , 1977, 80, 401-416.	2.4	45
155	Specific binding of the type C viral core protein p12 with purified viral RNA. <i>Cell</i> , 1976, 7, 21-32.	28.9	95
156	Baboons and their close relatives are unusual among primates in their ability to release nondefective endogenous type C viruses. <i>Virology</i> , 1976, 72, 278-282.	2.4	81
157	INTERSPECIES TRANSFER OF RNA TUMOR VIRUS GENES: IMPLICATIONS FOR THE SEARCH FOR "HUMAN" TYPE C VIRUSES. , 1976, , 369-384.		7
158	Infectious Primate Type C Virus Group: Evidence for an Origin from an Endogenous Virus of the Rodent, <i>Mus caroli</i> . <i>Proceedings of the International Symposium on Comparative Leukemia Research</i> , 1975, 43, 115-120.	0.1	1
159	Isolation of type-c viruses from the asian feral mouse <i>Mus musculus molossinus</i> . <i>International Journal of Cancer</i> , 1975, 15, 211-220.	5.1	50
160	Transplantable murine tumors release mouse-tropic and xenotropic type-c viruses. <i>International Journal of Cancer</i> , 1975, 15, 555-560.	5.1	14
161	Isolation of a type C virus (FS-1) from the European wildcat ( <i>Felis sylvestris</i> ). <i>Virology</i> , 1975, 66, 117-127.	2.4	15
162	Biologic and immunologic properties of porcine type C viruses. <i>Virology</i> , 1975, 66, 616-619.	2.4	90

#	ARTICLE	IF	CITATIONS
163	Infectious primate type C viruses: Three isolates belonging to a new subgroup from the brains of normal gibbons. <i>Virology</i> , 1975, 67, 335-343.	2.4	99
164	S-tropic murine type-C viruses: Frequency of isolation from continuous cell lines, leukemia virus preparations and normal spleens. <i>International Journal of Cancer</i> , 1974, 13, 587-598.	5.1	95
165	Infectious C-type virus isolated from a baboon placenta. <i>Nature</i> , 1974, 248, 17-20.	27.8	301
166	Endogenous baboon type C virus (M7): Biochemical and immunologic characterization. <i>Virology</i> , 1974, 58, 492-503.	2.4	76
167	Characterization of a type C virus released from the porcine cell line PK(15). <i>Virology</i> , 1974, 58, 65-74.	2.4	144
168	Radioimmunoassay of the major group specific protein of endogenous baboon type C viruses: Relation to the RD-114/CCC group and detection of antigen in normal baboon tissues. <i>Virology</i> , 1974, 61, 168-181.	2.4	85
169	Mixed splenocyte cultures and graft versus host reactions selectively induce an $\alpha$ S-tropic murine type C virus. <i>Cell</i> , 1974, 1, 55-58.	28.9	63
170	CELL SURFACE IMMUNOGLOBULIN. <i>Journal of Experimental Medicine</i> , 1972, 135, 1392-1405.	8.5	44
171	SYNTHESIS AND INTRACELLULAR TRANSPORT OF IMMUNOGLOBULIN IN SECRETORY AND NONSECRETORY CELLS *. <i>Annals of the New York Academy of Sciences</i> , 1971, 190, 250-267.	3.8	34
172	IMMUNOGLOBULIN SYNTHESIS AND SECRETION. <i>Journal of Experimental Medicine</i> , 1971, 133, 901-920.	8.5	47
173	Polymorphic control of subunit synthesis for the enzyme lactate dehydrogenase in the newt, <i>Triturus viridescens</i> . <i>The Journal of Experimental Zoology</i> , 1968, 169, 287-292.	1.4	6